BII announces that four companies have joined its new Venture House program. … Continue reading “BII announces new Venture House program and initial intake of four innovative companies”
BII today announces its investment into three international start-up companies from the … Continue reading “BII supports three international start-ups developing pioneering science in the therapeutics and health tech space”
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China”
LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs”
LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering”
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase … Continue reading “Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update”
Statistically significant improvements in key measures of lung function 42% reduction in … Continue reading “Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD”
New Investment from Forbion and Sofinnova Partners MANCHESTER, UK, 4 August 2022 – F2G … Continue reading “F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim”
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen … Continue reading “NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center”
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing … Continue reading “Versameb to present at the BIO Asia-Taiwan Conference”
• Focused on delivering highly effective vaccines against life-threatening respiratory viral infections … Continue reading “Vicebio launched by medicxi to advance the Molecular Clamp technology and develop next generation RSV vaccine”
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, … Continue reading “Doug Kohrs appointed to Sequana Medical Board of Directors”
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA … Continue reading “Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update”
FDA clarifies Phase 3 and US registration pathway for XF-73 Nasal gel … Continue reading “Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans”
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy Oegstgeest, … Continue reading “ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer”
MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical … Continue reading “Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance”
World leading expert and key opinion leader in nephrology Glasgow, Scotland, 13 … Continue reading “Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board”
Barcelona, July 13 2022, On 13 May 2022, the conformity assessment for … Continue reading “Declaration of conformity drawn up for Inbiomotion MAFTEST®”
Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of … Continue reading “Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
